Indian Giants Making Big Moves: Sun Pharma's Landmark Acquisition

Sun Pharmaceutical Industries Ltd's acquisition of US-based Organon & Co for USD 11.75 billion stands as the largest overseas acquisition by an Indian pharmaceutical company, ranking as India's second-largest outbound deal. This development highlights Indian firms' expanding global footprint through strategic international acquisitions.

In a significant development within the pharmaceutical industry, Sun Pharmaceutical Industries Ltd has announced a landmark acquisition of Organon & Co, a US-based company, for a whopping USD 11.75 billion. This acquisition marks the largest-ever overseas deal in the pharma sector by an Indian entity.

Notably, it ranks as India's second-largest outbound deal following Tata Steel's USD 12 billion takeover of Corus Group Plc in 2007. The transaction emphasizes the growing trend of Indian companies expanding their global influence through strategic acquisitions in international markets.

This move by Sun Pharmaceutical is poised to reshape the dynamics within the pharmaceutical landscape by integrating Organon's renowned offerings into its operations, further solidifying India's presence in the global market.